Literature DB >> 3492282

Immunochemically purified DR antigens in liposomes stimulate xenogeneic cytolytic T cells in secondary in vitro cultures.

J C Gorga, P J Knudsen, J A Foran, J L Strominger, S J Burakoff.   

Abstract

A monoclonal antibody directed against the human class II major histocompatibility antigen DR was generated. Use of this antibody, LB3.1, allowed isolation of large amounts of highly purified DR by immunoaffinity chromatography. The DR was reconstituted into liposomes and shown to stimulate secondary xenogeneic cytolytic T lymphocytes (CTL) specific for targets expressing DR antigens. DR digested with neuraminidase was equally as effective as native DR at stimulating CTL, while denatured DR and other purified membrane proteins were much less effective. The DR liposome-induced CTL lysed only target cells expressing class II antigens. Cytolysis of targets bearing class II antigens was blocked by DR-specific antisera.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3492282     DOI: 10.1016/0008-8749(86)90077-8

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  15 in total

1.  A point mutation in the groove of HLA-DO allows egress from the endoplasmic reticulum independent of HLA-DM.

Authors:  Francis Deshaies; Alexandre Brunet; Djibril A Diallo; Lisa K Denzin; Angela Samaan; Jacques Thibodeau
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-22       Impact factor: 11.205

2.  Analysis of the DR beta chains from two DRw6 cell lines (WT46 and WT52): recombination in vivo may have generated new haplotypes.

Authors:  P J Knudsen; J McLean; J L Strominger
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

3.  Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics.

Authors:  Anthony W Purcell; Sri H Ramarathinam; Nicola Ternette
Journal:  Nat Protoc       Date:  2019-05-15       Impact factor: 13.491

4.  Phenotypic and functional characterization of human cytolytic T cells lacking expression of CD5.

Authors:  B E Bierer; Y Nishimura; S J Burakoff; B R Smith
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

5.  Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules.

Authors:  K Falk; O Rötzschke; S Stevanović; G Jung; H G Rammensee
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

6.  Second-generation peptidomimetic inhibitors of antigen presentation effectively treat autoimmune diseases in HLA-DR-transgenic mouse models.

Authors:  Edward F Rosloniec; Tilmann Brandstetter; Sigmar Leyer; Franz-Werner Schwaiger; Zoltan A Nagy
Journal:  J Autoimmun       Date:  2006-11-01       Impact factor: 7.094

7.  L cells expressing DQ molecules of the DR3 and DR4 haplotypes: reactivity patterns with mAbs.

Authors:  D S Monos; E Czanky; S J Ono; S F Radka; D Kappes; J L Strominger
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

8.  Class II-antigen-negative patient and mutant B-cell lines represent at least three, and probably four, distinct genetic defects defined by complementation analysis.

Authors:  B Bénichou; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

9.  Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients.

Authors:  A Valli; A Sette; L Kappos; C Oseroff; J Sidney; G Miescher; M Hochberger; E D Albert; L Adorini
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

10.  Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation.

Authors:  Sarah Nikiforow; Kim Bottomly; George Miller; Christian Münz
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.